SCHEMBL6512272

SCHEMBL6512272

CC(OC(=O)Nc1ccc(Cl)c(Cl)c1)c1nc2ccc(Cl)c(Cl)c2[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.46
HTT P42858 2/20 0.43
LMNA P02545 1/20 0.43
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
AGPAT2 O15120 1/20 0.40
NPY1R P25929 1/20 0.40
NPY2R P49146 1/20 0.40
EPHX1 P07099 1/20 0.39
EPHX2 P34913 1/20 0.39
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
HPGD P15428 3/20 0.38
CYP3A4 P08684 1/20 0.38
APEX1 P27695 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TSHR P16473 2/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6512270 1.00 GRM5 (0.46) GRM5HTTLMNAKMT2AMEN1
SCHEMBL6511672 0.89 GRM5 (0.46) GRM5HTTLMNAKMT2AMEN1
SCHEMBL6511677 0.89 GRM5 (0.46) GRM5HTTLMNAKMT2AMEN1
SCHEMBL6511706 0.87 GRM5 (0.42) GRM5HTTLMNAKMT2AMEN1
SCHEMBL6512297 0.87 GRM5 (0.44) GRM5HTTLMNAKMT2AMEN1
SCHEMBL6512288 0.87 GRM5 (0.44) GRM5HTTLMNAKMT2AMEN1
SCHEMBL6515185 0.87 GRM5 (0.42) GRM5HTTLMNAKMT2AMEN1
SCHEMBL6511712 0.87 GRM5 (0.42) GRM5HTTLMNAKMT2AMEN1
SCHEMBL6514995 0.85 GRM5 (0.43) GRM5HTTLMNAKMT2AMEN1
SCHEMBL6514987 0.85 GRM5 (0.43) GRM5HTTLMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050148643-A1 Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme AGOURON PHARMACEUTICALS, INC. 2005-07-07 US claimed
US-20050148643-A1 Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme AGOURON PHARMACEUTICALS, INC. 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148643-A1 Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme CHEK1, CHEK2, RAD1 GRM5 4202/4885HTT 4339/4885LMNA 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.